Kyowa Kirin Co (4151) AI Stock Analysis

• Market Cap: ¥1.12T
• Dividend Yield: 2.61%
• Average Volume (3M): 1.24M
• Price to Earnings (P/E): 22.0
• Beta (1Y): 0.38
• Revenue Growth: 8.90%
• EPS Growth: -37.00%
• Country: JP
• Employees: 5,669
• Sector: Healthcare
• Sector Strength: 48
• Industry: Drug Manufacturers - General
• EPS (TTM): 11.78
• Shares Outstanding: 525,634,500
• 10 Day Avg. Volume: 1,330,080
• 30 Day Avg. Volume: 1,243,363
• PEG Ratio: -0.68
• Price to Book (P/B): 1.34
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 57.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,533.49
• Price Target Upside: 14.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

Kyowa Kirin Co's strong financial performance, characterized by solid revenue growth and a robust balance sheet, significantly boosts its stock score. However, technical analysis indicates bearish trends, and valuation metrics show a fairly balanced state. The absence of earnings call and corporate event data slightly limits the analysis but does not significantly detract from the overall positive position.

Kyowa Kirin Co Business Overview & Revenue Model

Company Description

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

How the Company Makes Money

Kyowa Kirin Co. generates revenue through the sale of its pharmaceutical products, which are developed internally or through partnerships. The company's key revenue streams include the commercialization of its proprietary drugs in global markets, earning income from product sales and licensing agreements. Additionally, Kyowa Kirin collaborates with other pharmaceutical companies and research institutions, engaging in joint ventures and co-development agreements that contribute to its earnings. The company also invests in ongoing research and development to expand its pipeline of drug candidates, ensuring a steady flow of innovative products to maintain and grow its market presence.

Kyowa Kirin Co Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
495.56B	442.23B	398.37B	352.25B	318.35B
	Gross Profit
362.95B	331.03B	311.46B	264.40B	237.91B
	EBIT
91.87B	95.84B	68.66B	61.17B	52.56B
	EBITDA
116.65B	118.53B	82.81B	79.86B	74.71B
	Net Income Common Stockholders
59.87B	81.19B	53.57B	52.35B	47.03B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
246.39B	405.01B	339.72B	336.52B	287.65B
	Total Assets
1.07T	1.03T	939.88B	921.87B	801.29B
	Total Debt
0.00	0.00	23.28B	22.54B	18.28B
	Net Debt
-244.68B	-403.08B	-315.92B	-312.55B	-268.74B
	Total Liabilities
216.55B	189.52B	177.06B	184.71B	102.89B
	Stockholders Equity
850.81B	836.42B	762.83B	737.16B	698.40B
Cash Flow		Free Cash Flow
41.85B	82.70B	20.01B	66.78B	4.27B
	Operating Cash Flow
67.88B	115.55B	48.67B	86.55B	39.50B
	Investing Cash Flow
-142.39B	-20.38B	-17.18B	-11.36B	252.56B
	Financing Cash Flow
-84.70B	-32.53B	-29.03B	-28.45B	-26.00B

Kyowa Kirin Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2218.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4151, the sentiment is Positive. The current price of 2218 is above the 20-day moving average (MA) of 2185.15, above the 50-day MA of 2171.44, and below the 200-day MA of 2518.95, indicating a neutral trend. The MACD of 5.91 indicates Positive momentum. The RSI at 54.02 is Neutral, neither overbought nor oversold. The STOCH value of 58.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4151.

Kyowa Kirin Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4151	74 Outperform	¥1.12T	21.98	6.04%	2.61%	8.90%	-37.00%
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%